-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Tromantadine hydrochloride
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/41544-24-5.gif)
| Category | Herpes simplex Virus (HSV) |
| CAS | 41544-24-5 |
| Description | Tromantadine hydrochloride, a derivative of amantadine, has anti-herpetic activity and inhibits herpes simplex virus type 1 (HSV-1) and HSV-2 replication. |
Product Information
| Synonyms | Virumerz; 2-(2-(Dimethylamino)ethoxy)-N-tricyclo(3.3.1.13,7)dec-1-ylacetamide monohydrochloride; Viruserol; Viru-merz; Acetamide, 2-[2-(dimethylamino)ethoxy]-N-tricyclo[3.3.1.13,7]dec-1-yl-, hydrochloride (1:1); 1-(Dimethylaminoethoxyacetamido)adamantane hydrochloride |
| IUPAC Name | N-(1-adamantyl)-2-[2-(dimethylamino)ethoxy]acetamide;hydrochloride |
| Molecular Weight | 316.87 |
| Molecular Formula | C16H29ClN2O2 |
| Canonical SMILES | CN(C)CCOCC(=O)NC12CC3CC(C1)CC(C3)C2.Cl |
| InChI | InChI=1S/C16H28N2O2.ClH/c1-18(2)3-4-20-11-15(19)17-16-8-12-5-13(9-16)7-14(6-12)10-16;/h12-14H,3-11H2,1-2H3,(H,17,19);1H |
| InChIKey | BPRCWSNCXPHMIW-UHFFFAOYSA-N |
| Boiling Point | 434.5°C at 760 mmHg |
| Melting Point | 157-158°C |
| Flash Point | 216.6°C |
| Purity | ≥98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid Powder |
| Application | Antiviral Agents |
| Storage | Store at 2-8°C, sealed storage, away from moisture |
| Complexity | 326 |
| Exact Mass | 316.1917559 |
| In Vitro | Treatment of the cells with 10 to 50μg of Tromantadine reduces HSV-induced cytopathic effect. Treatment with 100 to 500μg of Tromantadine inhibits herpes simplex virus-induced cytopathic effect and reduces virus production. Complete inhibition of virus production is observed with treatments of 500μg to 1 mg. The antiherpetic activity of Tromantadine is dependent upon the viral inoculum size and the time of addition of the compound with respect to infection. |
| PSA | 45.06000 |
| Target | HSV-1, HSV-2 |
